Zolpidem for Autism Spectrum Disorder
Study Summary
This trial is studying how a drug (zolpidem) affects sleep in kids and teens with autism, using techniques like polysomnography and actigraphy.
- Autism Spectrum Disorder
- Autism
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Is there an age-restriction for enrollment in this research experiment?
"This research study allows for volunteers between the ages of 8 and 17, in accordance with its eligibility requirements."
Has Zolpidem been given the green light by the FDA?
"Our assessment of Zolpidem's safety falls at a 2 as there is limited evidence indicating its efficacy, though much more exists in regards to the drug's security."
Could you provide an estimate of the people enrolled in this medical experiment?
"Affirmative. Clinicaltrials.gov data shows that this medical inquiry, which was first posted on July 12th 2023, is actively seeking new participants. Approximately 26 individuals must be recruited from a single site."
Is enrollment for this medical experiment currently available?
"Confirmed, this clinical trial is actively recruiting participants. Initially posted on July 12th 2023 with a recent update occurring the following day; information can be found on clinicaltrials.gov."
What eligibility requirements must be met to participate in this trial?
"This experiment is seeking 26 children aged 8-17 with Autism Spectrum Disorder (ASD). Necessary criteria for enrolment include: outpatient status between ages 8 and 17 during year one, DSM-5 diagnosis of ASD confirmed by the ADI-R and the ADOS-2 tests, gender non specific, PSG data available as well as actigraphy results from a CSHQ score higher than 41 with a sleep efficiency lower than 80%, reliable care providers to interact regularly with participants and accompany them to appointments while maintaining stable medication regimens for 4 weeks or more, willingness to provide saliva samples and take part in key procedures such as"